Cargando…

Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659

Evaluating the safety of probiotic microorganisms is an important part of the development of probiotic products. In this study, we have performed a systematic safety assessment of Limosilactobacillus reuteri American Type Culture Collection (ATCC) PTA 4659 based on genome analysis, antibiotic suscep...

Descripción completa

Detalles Bibliográficos
Autores principales: Sendelius, Malin, Axelsson, Jakob, Liu, Peidi, Roos, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689046/
https://www.ncbi.nlm.nih.gov/pubmed/37974056
http://dx.doi.org/10.1093/jimb/kuad041
_version_ 1785152287926124544
author Sendelius, Malin
Axelsson, Jakob
Liu, Peidi
Roos, Stefan
author_facet Sendelius, Malin
Axelsson, Jakob
Liu, Peidi
Roos, Stefan
author_sort Sendelius, Malin
collection PubMed
description Evaluating the safety of probiotic microorganisms is an important part of the development of probiotic products. In this study, we have performed a systematic safety assessment of Limosilactobacillus reuteri American Type Culture Collection (ATCC) PTA 4659 based on genome analysis, antibiotic susceptibility testing, phenotypic characterization, and a human clinical safety study. Genome sequence analysis showed that the strain is free from virulence and antibiotic resistance genes. Connected to this, phenotypic characterization showed that the strain is susceptible to the main classes of antibiotics. Limosilactobacillus reuteri ATCC PTA 4659 was shown to produce histamine, which has previously been described as an anti-inflammatory mediator produced by certain L. reuteri strains. However, the amount of histamine, a biogenic amine, poses no safety concern of a potential product. The strain was investigated in a human clinical safety study and was shown to survive passage through the gastrointestinal tract, both when administered at high [1 × 10(11) colony-forming units (CFU)/day] and low doses (1 × 10(9) CFU/day). The clinical safety evaluation showed that the doses administered are safe for human consumption. Furthermore, carbohydrate utilization, mucus adhesion, and tolerance to acid and bile were studied. It was shown that L. reuteri ATCC PTA 4659 has a very high adhesion to mucus and tolerance to both gastric pH and bile, all potentially important properties for a probiotic strain. Altogether, this study has demonstrated that Limosilactobacillus reuteri ATCC PTA 4659 is safe for human consumption and along with its phenotypic characteristics and previously described anti-inflammatory effects, makes it a promising strain for future probiotic development. NCT01033539
format Online
Article
Text
id pubmed-10689046
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106890462023-12-01 Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659 Sendelius, Malin Axelsson, Jakob Liu, Peidi Roos, Stefan J Ind Microbiol Biotechnol Food Biotechnology & Probiotics Evaluating the safety of probiotic microorganisms is an important part of the development of probiotic products. In this study, we have performed a systematic safety assessment of Limosilactobacillus reuteri American Type Culture Collection (ATCC) PTA 4659 based on genome analysis, antibiotic susceptibility testing, phenotypic characterization, and a human clinical safety study. Genome sequence analysis showed that the strain is free from virulence and antibiotic resistance genes. Connected to this, phenotypic characterization showed that the strain is susceptible to the main classes of antibiotics. Limosilactobacillus reuteri ATCC PTA 4659 was shown to produce histamine, which has previously been described as an anti-inflammatory mediator produced by certain L. reuteri strains. However, the amount of histamine, a biogenic amine, poses no safety concern of a potential product. The strain was investigated in a human clinical safety study and was shown to survive passage through the gastrointestinal tract, both when administered at high [1 × 10(11) colony-forming units (CFU)/day] and low doses (1 × 10(9) CFU/day). The clinical safety evaluation showed that the doses administered are safe for human consumption. Furthermore, carbohydrate utilization, mucus adhesion, and tolerance to acid and bile were studied. It was shown that L. reuteri ATCC PTA 4659 has a very high adhesion to mucus and tolerance to both gastric pH and bile, all potentially important properties for a probiotic strain. Altogether, this study has demonstrated that Limosilactobacillus reuteri ATCC PTA 4659 is safe for human consumption and along with its phenotypic characteristics and previously described anti-inflammatory effects, makes it a promising strain for future probiotic development. NCT01033539 Oxford University Press 2023-11-16 /pmc/articles/PMC10689046/ /pubmed/37974056 http://dx.doi.org/10.1093/jimb/kuad041 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Society of Industrial Microbiology and Biotechnology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Food Biotechnology & Probiotics
Sendelius, Malin
Axelsson, Jakob
Liu, Peidi
Roos, Stefan
Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659
title Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659
title_full Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659
title_fullStr Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659
title_full_unstemmed Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659
title_short Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659
title_sort genomic, phenotypic, and clinical safety of limosilactobacillus reuteri atcc pta 4659
topic Food Biotechnology & Probiotics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689046/
https://www.ncbi.nlm.nih.gov/pubmed/37974056
http://dx.doi.org/10.1093/jimb/kuad041
work_keys_str_mv AT sendeliusmalin genomicphenotypicandclinicalsafetyoflimosilactobacillusreuteriatccpta4659
AT axelssonjakob genomicphenotypicandclinicalsafetyoflimosilactobacillusreuteriatccpta4659
AT liupeidi genomicphenotypicandclinicalsafetyoflimosilactobacillusreuteriatccpta4659
AT roosstefan genomicphenotypicandclinicalsafetyoflimosilactobacillusreuteriatccpta4659